Unapproved weight-loss drug retatrutide widely available online, creating challenges for clinicians
By
Marilynn Larkin
Summary
Retatrutide, an investigational triple hormone receptor agonist not yet approved by the FDA for any indication, is being widely sold online and prescribed by licensed physicians across the US. Patients discover the drug through social media and purchase it from online vendors, creating an unprecedented situation where an unapproved drug is easily accessible. This leaves clinicians struggling with how to manage patients who are already taking the drug, navigating ethical, legal, and medical challenges without clear regulatory guidance.
Source
Twitter / XUnapproved weight-loss drug retatrutide widely available online, creating challenges for cliniciansmdsc.peKey quotes
· 3 pulledThe phenomenon of such easy access to a drug that's not approved anywhere for any indication is arguably without precedent.
Patients are discovering the drug — a GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon agonist — through social media, purchasing it from vendors online.
Non-FDA approved retatrutide is readily available to US consumers from multiple sources, leaving many clinicians grappling with how to manage patients taking the drug.
You might also wanna read
Triple hormone drug retatrutide shows promise for diabetes and weight loss in Lancet trial
A new triple hormone drug called retatrutide, which mimics GLP-1, GIP, and glucagon, has shown promising results in a Lancet-published trial
theguardian.com·21d ago
ClinicalTrials.gov
clinicaltrials.gov·5d ago
The unregulated peptide boom: Americans risk unknown side effects for quick-fix weight loss and anti-aging drugs
Thousands of Americans are using unregulated peptides purchased online for weight loss, muscle growth, and anti-aging purposes, despite thes
theguardian.com·12d ago
Replimune to resubmit melanoma drug for FDA approval after agency leadership changes
Replimune plans to resubmit its melanoma drug for FDA approval following a leadership shakeup at the agency. The drug was twice rejected und
cnb.cx·1mo ago
National Psoriasis Foundation Review Examines GLP-1 Receptor Agonists for Psoriasis with Metabolic Comorbidities
This review from the US National Psoriasis Foundation Medical Board provides an evidence-informed narrative synthesis on GLP-1 receptor agon
doi.org·1mo ago
FDA Announces Plans to Restrict Non-Approved GLP-1 Drugs in Compounded Medications
The FDA is announcing its intent to take action against non-FDA-approved GLP-1 drugs, specifically targeting GLP-1 active pharmaceutical ing
fda.gov·4mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.